Want to see GB:AZN full AI Analyst Report?

AstraZeneca (AZN) Share Forecast & Price Target

1,056 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZN Analyst Ratings

Strong Buy

14 Buy

2 Hold

0 Sell

Based on 16 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

15,691.28 p

▲(25.77% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 15,691.28 p with a high forecast of 19,800.00 p and a low forecast of 11,700.00 p. The average price target represents a 25.77% change from the last price of 12,476.00 p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11699":"11,699 p","15750":"15,750 p","19801":"19,801 p","13724.5":"13,724.5 p","17775.5":"17,775.5 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">20K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15691.284848857142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">16K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">12K </span>\n  </div></div>","useHTML":true}}],"tickPositions":[11699,13724.5,15750,17775.5,19801],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12032,12629.538461538461,13227.076923076924,13824.615384615385,14422.153846153846,15019.692307692309,15617.23076923077,16214.76923076923,16812.30769230769,17409.846153846156,18007.384615384617,18604.923076923078,19202.46153846154,{"y":19800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12032,12313.483449912088,12594.966899824176,12876.450349736264,13157.933799648352,13439.41724956044,13720.900699472528,14002.384149384616,14283.867599296704,14565.351049208792,14846.83449912088,15128.317949032966,15409.801398945054,{"y":15691.284848857142,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12032,12006.461538461539,11980.923076923076,11955.384615384615,11929.846153846154,11904.307692307691,11878.76923076923,11853.23076923077,11827.692307692309,11802.153846153846,11776.615384615385,11751.076923076924,11725.538461538461,{"y":11700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12227.076,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12260.505,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13603.557,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13558.328,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13804.129,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15151.259,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14922.778,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13422.751,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13345.267,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13762.492,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12548.563,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11962,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 72,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12032,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target19,800 p

Average Price Target15,691 p

Lowest Price Target11,700 p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Gordon CFA

Barclays

16,000 p

Buy

28.25%

Upside

Reiterated

10/26/26

Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

16,000 p

Buy

28.25%

Upside

Reiterated

10/26/26

AstraZeneca (AZN) Receives a Buy from J.P. Morgan

Trung Huynh

RBC Capital

14,500 p

Buy

16.22%

Upside

Reiterated

10/20/26

AstraZeneca (AZN) Gets a Buy from RBC Capital

Michael Leuchten

Jefferies

17,500 p

Buy

40.27%

Upside

Reiterated

10/20/26

AstraZeneca (AZN) Receives a Buy from Jefferies

Luisa Hector

Berenberg Bank

15,000 p

Buy

20.23%

Upside

Reiterated

10/16/26

Berenberg Bank Remains a Buy on AstraZeneca (AZN)

Colin White

UBS

15,200 p

Buy

21.83%

Upside

Reiterated

10/15/26

AstraZeneca (AZN) Receives a Buy from UBS

Emmanuel Papadakis

Deutsche Bank

11,700 p

Hold

-6.22%

Downside

Reiterated

10/14/26

Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)

Unknown Analyst

Nordea Markets

Not Ranked

Nordea Markets

12,424.34 p→14,306.81 p

Buy

14.67%

Upside

Upgraded

10/13/26

AstraZeneca upgraded to Buy from Sell at NordeaAstraZeneca upgraded to Buy from Sell at Nordea

Graham Parry

Citi

―

Buy

―

Reiterated

10/12/26

Citi Sticks to Its Buy Rating for AstraZeneca (AZN)

Justin Smith

Bernstein

20,200 p→19,800 p

Buy

58.70%

Upside

Reiterated

10/07/26

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Sachin Jain

Bank of America Securities

16,500 p

Buy

32.25%

Upside

Reiterated

10/05/26

AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target

Rajan Sharma

Goldman Sachs

16,526 p

Buy

32.46%

Upside

Reiterated

09/29/26

AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN

Rajesh Kumar

HSBC

13,750 p→13,920 p

Hold

11.57%

Upside

Reiterated

09/10/26

AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC

Steve Scala

TD Cowen

17,931.6 p

Buy

43.73%

Upside

Reiterated

08/31/26

Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside

Unknown Analyst

CICC

Not Ranked

CICC

14,793.57 p

Buy

18.58%

Upside

Initiated

08/24/26

AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Gordon CFA

Barclays

16,000 p

Buy

28.25%

Upside

Reiterated

10/26/26

Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

16,000 p

Buy

28.25%

Upside

Reiterated

10/26/26

AstraZeneca (AZN) Receives a Buy from J.P. Morgan

Trung Huynh

RBC Capital

14,500 p

Buy

16.22%

Upside

Reiterated

10/20/26

AstraZeneca (AZN) Gets a Buy from RBC Capital

Michael Leuchten

Jefferies

17,500 p

Buy

40.27%

Upside

Reiterated

10/20/26

AstraZeneca (AZN) Receives a Buy from Jefferies

Luisa Hector

Berenberg Bank

15,000 p

Buy

20.23%

Upside

Reiterated

10/16/26

Berenberg Bank Remains a Buy on AstraZeneca (AZN)

Colin White

UBS

15,200 p

Buy

21.83%

Upside

Reiterated

10/15/26

AstraZeneca (AZN) Receives a Buy from UBS

Emmanuel Papadakis

Deutsche Bank

11,700 p

Hold

-6.22%

Downside

Reiterated

10/14/26

Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)

Unknown Analyst

Nordea Markets

Not Ranked

Nordea Markets

12,424.34 p→14,306.81 p

Buy

14.67%

Upside

Upgraded

10/13/26

AstraZeneca upgraded to Buy from Sell at NordeaAstraZeneca upgraded to Buy from Sell at Nordea

Graham Parry

Citi

―

Buy

―

Reiterated

10/12/26

Citi Sticks to Its Buy Rating for AstraZeneca (AZN)

Justin Smith

Bernstein

20,200 p→19,800 p

Buy

58.70%

Upside

Reiterated

10/07/26

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Sachin Jain

Bank of America Securities

16,500 p

Buy

32.25%

Upside

Reiterated

10/05/26

AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target

Rajan Sharma

Goldman Sachs

16,526 p

Buy

32.46%

Upside

Reiterated

09/29/26

AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN

Rajesh Kumar

HSBC

13,750 p→13,920 p

Hold

11.57%

Upside

Reiterated

09/10/26

AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC

Steve Scala

TD Cowen

17,931.6 p

Buy

43.73%

Upside

Reiterated

08/31/26

Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside

Unknown Analyst

CICC

Not Ranked

CICC

14,793.57 p

Buy

18.58%

Upside

Initiated

08/24/26

AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

VSTMVerastem

HROWHarrow Health

IRTCIrhythm Technologies

DNLIDenali Therapeutics

IDYAIDEAYA Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months

Luisa HectorBerenberg Bank

Success Rate

32/53 ratings generated profit

Average Return

+2.71%

Copying Luisa Hector's trades and holding each position for 3 Months would result in 60.38% of your transactions generating a profit, with an average return of +2.71% per trade.

1 Year

Luisa HectorBerenberg Bank

Success Rate

39/53 ratings generated profit

Average Return

+11.15%

Copying Luisa Hector's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +11.15% per trade.

2 Years

Luisa HectorBerenberg Bank

Success Rate

44/53 ratings generated profit

Average Return

+19.50%

Copying Luisa Hector's trades and holding each position for 2 Years would result in 83.02% of your transactions generating a profit, with an average return of +19.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZN has received 59 Buy Ratings, 4 Hold Ratings, and 5 Sell Ratings. AZN average Analyst price target in the past 3 months is 15,691.28.

Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is 1.94 p with a range of 1.85 p to 2.03 p. The previous quarter’s EPS was 1.97 p. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is 11.96B with a range of 11.79B to 12.14B . The previous quarter’s sales results were 11.46B . AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 15,691.28.

What is GB:AZN’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 25.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca PLC a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.

What is AstraZeneca PLC’s share price target?

The average share price target for AstraZeneca PLC is 15,691.28. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 19,800.00 p ,and the lowest forecast is 11,700.00 p. The average share price target represents 25.77% Increase from the current price of 12,476 p.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of AstraZeneca PLC?

To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AstraZeneca (AZN) Share Forecast & Price Target

AZN Analyst Ratings

AZN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZN Analyst Recommendation Trends

AZN Financial Forecast

AZN Earnings Forecast

AZN Sales Forecast

AZN Stock Forecast FAQ

Detailed List of Analyst Forecasts